KRT6A expression inversely correlates with treatment duration, predicting poor prognosis in NSCLC patients treated with adagrasib alone, as high KRT6A levels are associated with shorter survival, higher KEAP1 and STK11/LKB1 mutation rates, and promote NSCLC cell proliferation and invasion (44, 102, 103). Here, KRT6A is linked to non-small cell lung carcinoma.